Title:
ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/006117
Kind Code:
A1
Abstract:
Provided herein are antibodies and antigen-binding fragment thereof targeting CLL1, and chimeric antigen receptors (e.g., monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-CLL1 antigen-binding fragments thereof. Further provided are engineered immune effector cells (e.g., T cells) expressing the chimeric antigen receptors and methods of use thereof.
Inventors:
ZHANG YAFENG (CN)
ZHU YANLIANG (CN)
ZHOU NANNAN (CN)
YANG SHUAI (CN)
WU SHU (CN)
ZHU YANLIANG (CN)
ZHOU NANNAN (CN)
YANG SHUAI (CN)
WU SHU (CN)
Application Number:
PCT/CN2022/109528
Publication Date:
February 02, 2023
Filing Date:
August 01, 2022
Export Citation:
Assignee:
NANJING LEGEND BIOTECH CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K19/00
Domestic Patent References:
| WO2020052542A1 | 2020-03-19 | |||
| WO2020216238A1 | 2020-10-29 | |||
| WO2017091615A1 | 2017-06-01 | |||
| WO2020035676A1 | 2020-02-20 | |||
| WO2019164929A1 | 2019-08-29 |
Foreign References:
| US20160051651A1 | 2016-02-25 |
Other References:
LIU FANG; CAO YUANZHEN; PINZ KEVIN; MA YU; WADA MASAYUKI; CHEN KEVIN; MA GINA; SHEN JIAQI; TSE CHARLOTTE OLIVIA; SU YI; XIONG YISO: "First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), US , pages 901, XP086595277, ISSN: 0006-4971, DOI: 10.1182/blood-2018-99-110579
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF:
Previous Patent: MONITORING DEVICE, AND DISPLAY METHOD FOR TARGET OBJECT
Next Patent: ANTI-CD33 ANTIBODIES AND USES THEREOF
Next Patent: ANTI-CD33 ANTIBODIES AND USES THEREOF